PRAZOLE
Prazole Plus 40mg / 30mg 1 Capsule
₱73.00
- SKU:
- 019464
- Generic Name:
- Pantoprazole + Domperidone
Prazole Plus 40mg / 30mg 1 Capsule
₱73.00
| PRAZOLE PLUS | |
| a) Product Name | Prazole Plus |
| b) Product Description | Hyperacidity, Acid Reflux, & Peptic Ulcer Disease |
| c) Product Details: | |
| ●Contents/Ingredients: | Each capsule contains pantoprazole sodium sesquihydrate equivalent to |
| pantoprazole 40 mg as enteric-coated pellets and domperidone 30 mg as | |
| sustained-release (SR) pellets. | |
| ●Indication/Usage | Management of GERD; gastritis, NUD, gastric or duodenal ulcer, dyspepsia, |
| bloating, fullness, belching, nonsteroidal anti-inflammatory drug (NSAID)- | |
| induced dyspepsia. | |
| ●Dosage and Administration | One (1) capsule daily before breakfast |
| ●Warning and Precautions | Pantoprazole + Domperidone shall be given with care to patients with renal |
| dysfunction or hepatic dysfunction. | |
| ●Adverse Reaction | Pantoprazole: The adverse reactions associated with pantoprazole include |
| headache, diarrhea, skin rash, pruritus and dizziness. Domperidone: Serum | |
| prolactin level may rise resulting in galactorrhea in females and less | |
| frequently gynecomastia in males due to domperidone. Dry mouth, thirst, | |
| headache, nervousness, drowsiness, diarrhea, skin rashes and itching may | |
| follow treatment with domperidone. | |
| ●Drug Interactions | Pantoprazole |
| Pantoprazole is metabolized through the cytochrome P450 system, primarily | |
| the CYP2C19 and CYP3A4 isoenzymes, and subsequently undergoes phase II | |
| conjugation. Based on studies evaluating possible interactions of | |
| Pantoprazole with other drugs metabolized by the cytochrome P450 system, | |
| no dosage adjustment is needed with ccnccmitant use of the following drugs: | |
| theophylline, cisapride, antipyrine, caffeine, carbamezapine, diazepam, | |
| diclofenac, digoxin, ethanol, glyburide, oral ccntraceptives (Ievonorgestrel | |
| l ethynylestradiol), metoprolol, nifedipine, phenytoin or warfarin. Clinically | |
| relevant interactions of Pantoprazole with other drugs with the same | |
| metabolic pathways are not expected. Therefore, when co- administered with | |
| Pantoprazole, adjustment of the dosage of Pantoprazole with such drugs may | |
| not be necessary. There was also no interaction with concomitantly | |
| administered antacids. Because of profound and long lasting inhibition of | |
| gastric acid secretion, it is theoretically possible that Pantoprazole may | |
| interfere with absorption of drugs where gastric pH is an important | |
| determinant of their bioavailability (e.g. Ketoconazole, Ampicillin esters, and | |
| iron salts). | |
| Domperidone | |
| Anti-cholinergic drugs may inhibit the anti-dyspeptic effects of Domperidone. | |
| Antimuscarinic agents and opioid analgesics may antagonize the effect of | |
| Domperidone. Domperidone suppresses the peripheral effects (digestive | |
| disorders, nausea and vomiting) of dopaminergic agonists. Since Domperidone | |
| has gastro-kinetic effects, it could influence the absorption of concomitant | |
| orally administered drugs, particularly those with sustained release or enteric | |
| coated formulations. As Domperidone interferes with serum prolactin levels, it | |
| may interfere with other hypoprolactinaemic agents and with some diagnostic | |
| tests. Antacids and anti-secretory agents lower the oral bioavailability of | |
| Domperidone. They should be taken after meals and not before meals, i.e. | |
| they should not be taken simultaneously with Domperidone. Reduced gastric | |
| acidity impairs the absorption of Domperidone. Oral bioavailability is | |
| decreased by prior administration of Cimetidine or Sodium Carbonate. | |
| ●Contradiction | Hypersensitivity |
| ●Requires prescription? | Yes |
| ●Overdose and Treatment | In the event of overdosage, gastric lavage should be performed. Symptomatic |
| and supportive measures are recommended. | |
| ●Storage Conditions | Store at temperature not exceeding 30 degree Celsius |
| ●Drug Abuse & Dependence | None |
| d) Product Information | |
| ●Generic Name | Pantoprazole/ Domperidone |
| ●Strength | 40mg/ 30mg |
| ●Dosage Form | Capsule |
| ●Manufacturer | Inventia Healthcare Pvt. Ltd. |
| ●Place of Origin | India |
| ●Brand | Prazole Plus |
| ●Class Name | Proton pump inhibitors |
| ●Classification | A02BC02 |
| ●Regulatory Classification | Prescription Drug |
